Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CASTLE BIOSCIENCES INCCSTL · Entity 359 | Director · Pres. & Chief Exec. Officer | October 05, 2026 | October 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CASTLE BIOSCIENCES INC
Report date October 05, 2026 · Filed October 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,064 |
Ending reported balance
After 2026-10-05 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-05 · Exercise / conversion · Acquired 8,165 · Balance 29,644 F1: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2026. Row 2 · 2026-10-05 · Sale · Disposed 8,580 · Balance 21,064 F1: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2026. F2: This transaction was executed in multiple trades at prices ranging from $35.310 to $35.965, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| Common StockSEC Table I · non-derivative | IndirectBy The Maetzold Descendants 2020 Trust | 8,038 |
Reported balance
After 2026-10-05 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2026-10-05 · Sale · Disposed 3,198 · Balance 8,038 F1: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2026. F2: This transaction was executed in multiple trades at prices ranging from $35.310 to $35.965, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3: Held by The Maetzold Descendants 2020 Trust of which the Reporting Person's spouse is the trustee and the Reporting Person's spouse and their children are beneficiaries. |
| Common StockSEC Table I · non-derivative | IndirectBy Derek Maetzold 2020 Irrevocable Trust | 6,832 |
Reported balance
After 2026-10-05 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2026-10-05 · Sale · Disposed 2,718 · Balance 6,832 F1: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2026. F2: This transaction was executed in multiple trades at prices ranging from $35.310 to $35.965, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4: Held by Derek Maetzold 2020 Irrevocable Trust of which the Reporting Person is the trustee and his children are beneficiaries. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.39 · Expires 2028-05-09 | Direct | 0 |
Reported balance
After 2026-10-05 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2026-10-05 · Exercise / conversion · Disposed 8,165 · Balance 0 F1: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2026. F13: The shares subject to the option are fully vested. |
| Common StockSEC Table I · non-derivative | IndirectBy The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk | 11,256 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 11,256 F5: Held by The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk of which the Reporting Person is the trustee and his child is the beneficiary. |
| Common StockSEC Table I · non-derivative | IndirectBy The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold | 11,256 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 11,256 F6: Held by The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. |
| Common StockSEC Table I · non-derivative | IndirectBy The Maetzold 2018 Remainder Trust FBO John Derek Maetzold | 11,256 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 11,256 F7: Held by The Maetzold 2018 Remainder Trust FBO John Derek Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. |
| Common StockSEC Table I · non-derivative | IndirectBy The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold | 11,256 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 11,256 F8: Held by The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. |
| Common StockSEC Table I · non-derivative | IndirectBy DJM Grantor Retained Annuity Trust No. 6 | 11,963 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 9
Holding and transaction disclosures are not merged.
1 source rowRow 9 · Balance 11,963 F9: Held by DJM Grantor Retained Annuity Trust No. 6 of which the Reporting Person is the trustee and the beneficiaries are The Maetzold 2018 Remainder Trust FBO John Derek Maetzold, The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk, The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold and The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold. |
| Common StockSEC Table I · non-derivative | IndirectBy DJM Grantor Retained Annuity Trust No. 7 | 27,862 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 10
Holding and transaction disclosures are not merged.
1 source rowRow 10 · Balance 27,862 F10: Held by DJM Grantor Retained Annuity Trust No. 7 of which the Reporting Person is the trustee and beneficiary. |
| Common StockSEC Table I · non-derivative | IndirectBy DJM Grantor Retained Annuity Trust No. 8 | 40,935 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 11
Holding and transaction disclosures are not merged.
1 source rowRow 11 · Balance 40,935 F11: Held by DJM Grantor Retained Annuity Trust No. 8 of which the Reporting Person is the trustee and beneficiary. |
| Common StockSEC Table I · non-derivative | IndirectDJM Grantor Retained Annuity Trust No. 9 | 23,216 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 12
Holding and transaction disclosures are not merged.
1 source rowRow 12 · Balance 23,216 F12: Held by DJM Grantor Retained Annuity Trust No. 9 of which the Reporting Person is the trustee and beneficiary. |
Filing footnotes · ownership attribution and instrument terms
F1: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2026.
F2: This transaction was executed in multiple trades at prices ranging from $35.310 to $35.965, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3: Held by The Maetzold Descendants 2020 Trust of which the Reporting Person's spouse is the trustee and the Reporting Person's spouse and their children are beneficiaries.
F4: Held by Derek Maetzold 2020 Irrevocable Trust of which the Reporting Person is the trustee and his children are beneficiaries.
F5: Held by The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk of which the Reporting Person is the trustee and his child is the beneficiary.
F6: Held by The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold of which the Reporting Person is the trustee and his child is the beneficiary.
F7: Held by The Maetzold 2018 Remainder Trust FBO John Derek Maetzold of which the Reporting Person is the trustee and his child is the beneficiary.
F8: Held by The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold of which the Reporting Person is the trustee and his child is the beneficiary.
F9: Held by DJM Grantor Retained Annuity Trust No. 6 of which the Reporting Person is the trustee and the beneficiaries are The Maetzold 2018 Remainder Trust FBO John Derek Maetzold, The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk, The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold and The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold.
F10: Held by DJM Grantor Retained Annuity Trust No. 7 of which the Reporting Person is the trustee and beneficiary.
F11: Held by DJM Grantor Retained Annuity Trust No. 8 of which the Reporting Person is the trustee and beneficiary.
F12: Held by DJM Grantor Retained Annuity Trust No. 9 of which the Reporting Person is the trustee and beneficiary.
F13: The shares subject to the option are fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 07, 2026 Filed May 11, 2026 20:06 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 985 | $22.08 | $21,748.80 |
DisclosureSEC source: 0001628280-26-033446 · wk-form4_1778529974.xml · nonDerivative · entry 4 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Derek Maetzold 2020 Irrevocable Trust Disclosed balance after: 39,382 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 3, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $21.520 to $22.515, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 · ownership.nature: Held by Derek Maetzold 2020 Irrevocable Trust of which the Reporting Person is the trustee and his children are beneficiaries. Read SEC document |
| May 07, 2026 Filed May 11, 2026 20:06 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,159 | $22.08 | $25,590.72 |
DisclosureSEC source: 0001628280-26-033446 · wk-form4_1778529974.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By The Maetzold Descendants 2020 Trust Disclosed balance after: 46,336 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 3, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $21.520 to $22.515, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by The Maetzold Descendants 2020 Trust of which the Reporting Person's spouse is the trustee and the Reporting Person's spouse and their children are beneficiaries. Read SEC document |
| May 07, 2026 Filed May 11, 2026 20:06 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 5,308 | $22.08 | $117,200.64 |
DisclosureSEC source: 0001628280-26-033446 · wk-form4_1778529974.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,385 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 3, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $21.520 to $22.515, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 07, 2026 Filed May 11, 2026 20:06 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionCommon Stock | 6,214 | $2.39 | $14,851.46 |
DisclosureSEC source: 0001628280-26-033446 · wk-form4_1778529974.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,693 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 3, 2025. Read SEC document |
| April 21, 2026 Filed Apr 23, 2026 20:16 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionStock option (right to buy) · Derivative | 550 | $0.00 Strike: $2.39 | $0.00 |
DisclosureSEC source: 0001628280-26-026851 · wk-form4_1776975402.xml · derivative · entry 12 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,968 Underlying: Common Stock · 550 shares Expires 2028-11-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 3, 2025. F12 · derivative.exercise_date: The shares subject to the option are fully vested. Read SEC document |
| April 21, 2026 Filed Apr 23, 2026 20:16 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 278 | $25.10 | $6,977.24 |
DisclosureSEC source: 0001628280-26-026851 · wk-form4_1776975402.xml · nonDerivative · entry 8 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold Disclosed balance after: 2,502 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 3, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $25.000 to $25.585, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F8 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| April 21, 2026 Filed Apr 23, 2026 20:16 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 278 | $25.10 | $6,977.24 |
DisclosureSEC source: 0001628280-26-026851 · wk-form4_1776975402.xml · nonDerivative · entry 7 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO John Derek Maetzold Disclosed balance after: 2,502 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 3, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $25.000 to $25.585, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F7 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO John Derek Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| April 21, 2026 Filed Apr 23, 2026 20:16 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 278 | $25.10 | $6,977.24 |
DisclosureSEC source: 0001628280-26-026851 · wk-form4_1776975402.xml · nonDerivative · entry 6 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold Disclosed balance after: 2,502 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 3, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $25.000 to $25.585, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F6 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| April 21, 2026 Filed Apr 23, 2026 20:16 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 278 | $25.10 | $6,977.24 |
DisclosureSEC source: 0001628280-26-026851 · wk-form4_1776975402.xml · nonDerivative · entry 5 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk Disclosed balance after: 2,502 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 3, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $25.000 to $25.585, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F5 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| April 21, 2026 Filed Apr 23, 2026 20:16 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,153 | $25.10 | $28,937.99 |
DisclosureSEC source: 0001628280-26-026851 · wk-form4_1776975402.xml · nonDerivative · entry 4 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Derek Maetzold 2020 Irrevocable Trust Disclosed balance after: 40,367 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 3, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $25.000 to $25.585, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 · ownership.nature: Held by Derek Maetzold 2020 Irrevocable Trust of which the Reporting Person is the trustee and his children are beneficiaries. Read SEC document |
| April 21, 2026 Filed Apr 23, 2026 20:16 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,357 | $25.10 | $34,057.99 |
DisclosureSEC source: 0001628280-26-026851 · wk-form4_1776975402.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By The Maetzold Descendants 2020 Trust Disclosed balance after: 47,495 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 3, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $25.000 to $25.585, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by The Maetzold Descendants 2020 Trust of which the Reporting Person's spouse is the trustee and the Reporting Person's spouse and their children are beneficiaries. Read SEC document |
| April 21, 2026 Filed Apr 23, 2026 20:16 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 550 | $25.10 | $13,803.90 |
DisclosureSEC source: 0001628280-26-026851 · wk-form4_1776975402.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,479 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 3, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $25.000 to $25.585, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 21, 2026 Filed Apr 23, 2026 20:16 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionCommon Stock | 550 | $2.39 | $1,314.50 |
DisclosureSEC source: 0001628280-26-026851 · wk-form4_1776975402.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,029 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 3, 2025. Read SEC document |
| April 06, 2026 Filed Apr 8, 2026 20:34 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionStock option (right to buy) · Derivative | 6,214 | $0.00 Strike: $2.39 | $0.00 |
DisclosureSEC source: 0001628280-26-024264 · wk-form4_1775680461.xml · derivative · entry 12 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,518 Underlying: Common Stock · 6,214 shares Expires 2028-11-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 3, 2025. F12 · derivative.exercise_date: The shares subject to the option are fully vested. Read SEC document |
| April 06, 2026 Filed Apr 8, 2026 20:34 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 278 | $25.03 | $6,958.34 |
DisclosureSEC source: 0001628280-26-024264 · wk-form4_1775680461.xml · nonDerivative · entry 8 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold Disclosed balance after: 2,780 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 3, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $24.64 to $25.29, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F8 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| April 06, 2026 Filed Apr 8, 2026 20:34 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 278 | $25.03 | $6,958.34 |
DisclosureSEC source: 0001628280-26-024264 · wk-form4_1775680461.xml · nonDerivative · entry 7 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO John Derek Maetzold Disclosed balance after: 2,780 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 3, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $24.64 to $25.29, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F7 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO John Derek Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| April 06, 2026 Filed Apr 8, 2026 20:34 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 278 | $25.03 | $6,958.34 |
DisclosureSEC source: 0001628280-26-024264 · wk-form4_1775680461.xml · nonDerivative · entry 6 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold Disclosed balance after: 2,780 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 3, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $24.64 to $25.29, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F6 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| April 06, 2026 Filed Apr 8, 2026 20:34 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 278 | $25.03 | $6,958.34 |
DisclosureSEC source: 0001628280-26-024264 · wk-form4_1775680461.xml · nonDerivative · entry 5 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk Disclosed balance after: 2,780 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 3, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $24.64 to $25.29, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F5 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| April 06, 2026 Filed Apr 8, 2026 20:34 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,153 | $25.03 | $28,859.59 |
DisclosureSEC source: 0001628280-26-024264 · wk-form4_1775680461.xml · nonDerivative · entry 4 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Derek Maetzold 2020 Irrevocable Trust Disclosed balance after: 41,520 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 3, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $24.64 to $25.29, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 · ownership.nature: Held by Derek Maetzold 2020 Irrevocable Trust of which the Reporting Person is the trustee and his children are beneficiaries. Read SEC document |
| April 06, 2026 Filed Apr 8, 2026 20:34 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,357 | $25.03 | $33,965.71 |
DisclosureSEC source: 0001628280-26-024264 · wk-form4_1775680461.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By The Maetzold Descendants 2020 Trust Disclosed balance after: 48,852 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 3, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $24.64 to $25.29, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by The Maetzold Descendants 2020 Trust of which the Reporting Person's spouse is the trustee and the Reporting Person's spouse and their children are beneficiaries. Read SEC document |
| April 06, 2026 Filed Apr 8, 2026 20:34 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 6,214 | $25.03 | $155,536.42 |
DisclosureSEC source: 0001628280-26-024264 · wk-form4_1775680461.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,479 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 3, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $24.64 to $25.29, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 06, 2026 Filed Apr 8, 2026 20:34 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionCommon Stock | 6,214 | $2.39 | $14,851.46 |
DisclosureSEC source: 0001628280-26-024264 · wk-form4_1775680461.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,693 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 3, 2025. Read SEC document |
| March 26, 2026 Filed Mar 30, 2026 22:29 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionStock option (right to buy) · Derivative | 550 | $0.00 Strike: $2.39 | $0.00 |
DisclosureSEC source: 0001628280-26-022135 · wk-form4_1774909763.xml · derivative · entry 12 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,732 Underlying: Common Stock · 550 shares Expires 2028-11-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 3, 2025. F12 · derivative.exercise_date: The shares subject to the option are fully vested. Read SEC document |
| March 26, 2026 Filed Mar 30, 2026 22:29 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 278 | $25.55 | $7,103.18 |
DisclosureSEC source: 0001628280-26-022135 · wk-form4_1774909763.xml · nonDerivative · entry 8 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold Disclosed balance after: 3,058 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 3, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $25.050 to $25.955, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F8 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| March 26, 2026 Filed Mar 30, 2026 22:29 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 278 | $25.55 | $7,103.18 |
DisclosureSEC source: 0001628280-26-022135 · wk-form4_1774909763.xml · nonDerivative · entry 7 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO John Derek Maetzold Disclosed balance after: 3,058 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 3, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $25.050 to $25.955, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F7 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO John Derek Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| March 26, 2026 Filed Mar 30, 2026 22:29 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 278 | $25.55 | $7,103.18 |
DisclosureSEC source: 0001628280-26-022135 · wk-form4_1774909763.xml · nonDerivative · entry 6 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold Disclosed balance after: 3,058 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 3, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $25.050 to $25.955, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F6 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| March 26, 2026 Filed Mar 30, 2026 22:29 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 278 | $25.55 | $7,103.18 |
DisclosureSEC source: 0001628280-26-022135 · wk-form4_1774909763.xml · nonDerivative · entry 5 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk Disclosed balance after: 3,058 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 3, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $25.050 to $25.955, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F5 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| March 26, 2026 Filed Mar 30, 2026 22:29 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,153 | $25.55 | $29,460.30 |
DisclosureSEC source: 0001628280-26-022135 · wk-form4_1774909763.xml · nonDerivative · entry 4 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Derek Maetzold 2020 Irrevocable Trust Disclosed balance after: 42,673 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 3, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $25.050 to $25.955, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 · ownership.nature: Held by Derek Maetzold 2020 Irrevocable Trust of which the Reporting Person is the trustee and his children are beneficiaries. Read SEC document |
| March 26, 2026 Filed Mar 30, 2026 22:29 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,357 | $25.55 | $34,672.71 |
DisclosureSEC source: 0001628280-26-022135 · wk-form4_1774909763.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By The Maetzold Descendants 2020 Trust Disclosed balance after: 50,209 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 3, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $25.050 to $25.955, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by The Maetzold Descendants 2020 Trust of which the Reporting Person's spouse is the trustee and the Reporting Person's spouse and their children are beneficiaries. Read SEC document |
| March 26, 2026 Filed Mar 30, 2026 22:29 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 550 | $25.55 | $14,053.05 |
DisclosureSEC source: 0001628280-26-022135 · wk-form4_1774909763.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,479 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 3, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $25.050 to $25.955, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 26, 2026 Filed Mar 30, 2026 22:29 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionCommon Stock | 550 | $2.39 | $1,314.50 |
DisclosureSEC source: 0001628280-26-022135 · wk-form4_1774909763.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,029 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 3, 2025. Read SEC document |
| March 18, 2026 Filed Mar 19, 2026 20:21 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 650 | $25.39 | $16,503.50 |
DisclosureSEC source: 0001628280-26-019823 · wk-form4_1773951683.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,479 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 3, 2025. F3 · price: This transaction was executed in multiple trades at prices ranging from $25.26 to $25.48, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 17, 2026 Filed Mar 19, 2026 20:21 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 18,650 | $25.93 | $483,594.50 |
DisclosureSEC source: 0001628280-26-019823 · wk-form4_1773951683.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,129 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 3, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $25.66 to $26.27, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 16, 2026 Filed Mar 17, 2026 20:36 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 126 | $26.68 | $3,361.68 |
DisclosureSEC source: 0001628280-26-018813 · wk-form4_1773779760.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,779 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 3, 2025. Read SEC document |
| March 16, 2026 Filed Mar 17, 2026 20:36 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 17,449 | $25.96 | $453,045.84 |
DisclosureSEC source: 0001628280-26-018813 · wk-form4_1773779760.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,905 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 3, 2025. F3 · price: This transaction was executed in multiple trades at prices ranging from $25.660 to $26.630, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 13, 2026 Filed Mar 17, 2026 20:36 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 13,204 | $25.45 | $336,002.19 |
DisclosureSEC source: 0001628280-26-018813 · wk-form4_1773779760.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 58,354 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 3, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $25.210 to $25.785, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 12, 2026 Filed Mar 13, 2026 20:10 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 23,179 | $25.28 | $585,941.94 |
DisclosureSEC source: 0001628280-26-017694 · wk-form4_1773432611.xml · nonDerivative · entry 9 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 71,558 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 3, 2025. F9 · price: This transaction was executed in multiple trades at prices ranging from $24.900 to $25.705, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 11, 2026 Filed Mar 13, 2026 20:10 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionStock option (right to buy) · Derivative | 6,226 | $0.00 Strike: $2.39 | $0.00 |
DisclosureSEC source: 0001628280-26-017694 · wk-form4_1773432611.xml · derivative · entry 13 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,282 Underlying: Common Stock · 6,226 shares Expires 2028-11-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 3, 2025. F13 · derivative.exercise_date: The shares subject to the option are fully vested. Read SEC document |
| March 11, 2026 Filed Mar 13, 2026 20:10 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 279 | $26.11 | $7,284.41 |
DisclosureSEC source: 0001628280-26-017694 · wk-form4_1773432611.xml · nonDerivative · entry 8 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold Disclosed balance after: 3,336 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 3, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $25.800 to $26.630, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F8 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| March 11, 2026 Filed Mar 13, 2026 20:10 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 279 | $26.11 | $7,284.41 |
DisclosureSEC source: 0001628280-26-017694 · wk-form4_1773432611.xml · nonDerivative · entry 7 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO John Derek Maetzold Disclosed balance after: 3,336 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 3, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $25.800 to $26.630, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F7 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO John Derek Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| March 11, 2026 Filed Mar 13, 2026 20:10 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 279 | $26.11 | $7,284.41 |
DisclosureSEC source: 0001628280-26-017694 · wk-form4_1773432611.xml · nonDerivative · entry 6 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold Disclosed balance after: 3,336 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 3, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $25.800 to $26.630, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F6 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| March 11, 2026 Filed Mar 13, 2026 20:10 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 282 | $26.11 | $7,362.74 |
DisclosureSEC source: 0001628280-26-017694 · wk-form4_1773432611.xml · nonDerivative · entry 5 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk Disclosed balance after: 3,336 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 3, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $25.800 to $26.630, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F5 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| March 11, 2026 Filed Mar 13, 2026 20:10 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,160 | $26.11 | $30,286.44 |
DisclosureSEC source: 0001628280-26-017694 · wk-form4_1773432611.xml · nonDerivative · entry 4 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Derek Maetzold 2020 Irrevocable Trust Disclosed balance after: 43,826 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 3, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $25.800 to $26.630, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 · ownership.nature: Held by Derek Maetzold 2020 Irrevocable Trust of which the Reporting Person is the trustee and his children are beneficiaries. Read SEC document |
| March 11, 2026 Filed Mar 13, 2026 20:10 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,357 | $26.11 | $35,429.91 |
DisclosureSEC source: 0001628280-26-017694 · wk-form4_1773432611.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By The Maetzold Descendants 2020 Trust Disclosed balance after: 51,566 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 3, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $25.800 to $26.630, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by The Maetzold Descendants 2020 Trust of which the Reporting Person's spouse is the trustee and the Reporting Person's spouse and their children are beneficiaries. Read SEC document |
| March 11, 2026 Filed Mar 13, 2026 20:10 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 17,310 | $26.11 | $451,946.79 |
DisclosureSEC source: 0001628280-26-017694 · wk-form4_1773432611.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 94,737 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 3, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $25.800 to $26.630, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 11, 2026 Filed Mar 13, 2026 20:10 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionCommon Stock | 6,226 | $2.39 | $14,880.14 |
DisclosureSEC source: 0001628280-26-017694 · wk-form4_1773432611.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 112,047 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 3, 2025. Read SEC document |
| March 04, 2026 Filed Mar 5, 2026 22:12 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionRestricted Stock Units · Derivative | 27,987 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-015344 · wk-form4_1772748733.xml · derivative · entry 15 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,961 Underlying: Common Stock · 27,987 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F14 · derivative.exercise_date: On March 4, 2025, the Reporting Person was granted 111,948 RSUs which vest in four equal installments beginning on March 4, 2026. F14 · derivative.expiration_date: On March 4, 2025, the Reporting Person was granted 111,948 RSUs which vest in four equal installments beginning on March 4, 2026. Read SEC document |
| March 04, 2026 Filed Mar 5, 2026 22:12 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionRestricted Stock Units · Derivative | 31,110 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-015344 · wk-form4_1772748733.xml · derivative · entry 14 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,218 Underlying: Common Stock · 31,110 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F13 · derivative.exercise_date: On March 4, 2024, the Reporting Person was granted 124,437 RSUs which vest in four equal installments beginning on March 4, 2025. F13 · derivative.expiration_date: On March 4, 2024, the Reporting Person was granted 124,437 RSUs which vest in four equal installments beginning on March 4, 2025. Read SEC document |
| March 04, 2026 Filed Mar 5, 2026 22:12 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Tax withholdingCommon Stock | 17,931 | $28.17 | $505,116.27 |
DisclosureSEC source: 0001628280-26-015344 · wk-form4_1772748733.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,821 Read SEC document |
| March 04, 2026 Filed Mar 5, 2026 22:12 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionCommon Stock | 59,097 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-015344 · wk-form4_1772748733.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,752 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.